Data being presented at the
upcoming AACR meeting show
that Guardant's liquid biopsy
test provided more accurate
and rapid mutation detection
than tissue genotyping.
CEO Brad Gray told investors
at the JP Morgan Healthcare
Conference that he believes
the firm's GeoMx has
advantages over competitors in
the new market.
José Baselga, the former chief
medical officer of Memorial
Sloan Kettering Cancer Center,
has now resigned as
editor-in-chief of a cancer
journal, the
New York Times and
ProPublica report.
The company is expecting that
existing users from its
technology access program are
likely to purchase instruments
when they become available
later this year.
The company is eyeing a launch
for its IVD kits at the
beginning of next year, as
evidence grows for the
integration of TMB analysis
into the clinical care of
cancer patients.
Investigators and commercial
firms presenting at the recent
AACR meeting highlighted how
heterogeneous both the
technology and the application
of liquid biopsy remains.
At the AACR annual meeting,
researchers highlighted
genomics- and
proteomics-informed research
aimed at establishing more
effective, targeted
immunotherapies.
